Another agent under investigation in a biomarker-unselected fashion is gedatolisib, evaluated in the VIKTORIA-01 phase III trial in combination with fulvestrant, with or without palbociclib, for HR+/HER2− advanced breast cancer previously treated with a CDK4/6 inhibitor. This evidence concerns the gene HR and breast carcinoma.